RECLAIM: Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of cIAI¹

As effective as a carbapenem when combined with metronidazole in hospitalised patients with Gram-negative cIAIs¹

An international, non-inferiority, randomised, double-blind, comparative, Phase III trial.¹
     • ZAVICEFTA plus metronidazole versus meropenem

Trial population:¹
     • cIAI requiring surgical intervention or percutaneous draining within 24 hours before or after randomisation
        – Randomised patients, N=1066
        – mMITT population, N=1043

Abbreviations:
AE, adverse event; CI, confidence interval; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; mMITT, microbiologically modified intention-to-treat; VAP, ventilator-associated pneumonia.

Reference:
1. Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9

*The 2 combined studies were sized to provide 90% power for a 10% non-inferiority margin and thus 95% power for a 12.5 non-inferiority margin.
^†Patients in the mMITT population are defined as carrying a pathogen at the start of treatment.